Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Cell Immunol. 2023 Apr 26;388-389:104719. doi: 10.1016/j.cellimm.2023.104719. Online ahead of print.ABSTRACTGraft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to ...
Source: Cellular Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Simone Dertschnig Jakob Passweg Christoph Bucher Michael Medinger Alexandar Tzankov Source Type: research
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Cell Immunol. 2023 Apr 26;388-389:104719. doi: 10.1016/j.cellimm.2023.104719. Online ahead of print.ABSTRACTGraft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to ...
Source: Cellular Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Simone Dertschnig Jakob Passweg Christoph Bucher Michael Medinger Alexandar Tzankov Source Type: research
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Cell Immunol. 2023 Apr 26;388-389:104719. doi: 10.1016/j.cellimm.2023.104719. Online ahead of print.ABSTRACTGraft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to ...
Source: Cellular Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Simone Dertschnig Jakob Passweg Christoph Bucher Michael Medinger Alexandar Tzankov Source Type: research
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Cell Immunol. 2023 Apr 26;388-389:104719. doi: 10.1016/j.cellimm.2023.104719. Online ahead of print.ABSTRACTGraft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to ...
Source: Cellular Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Simone Dertschnig Jakob Passweg Christoph Bucher Michael Medinger Alexandar Tzankov Source Type: research
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
Cell Immunol. 2023 Apr 26;388-389:104719. doi: 10.1016/j.cellimm.2023.104719. Online ahead of print.ABSTRACTGraft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to ...
Source: Cellular Immunology - May 4, 2023 Category: Allergy & Immunology Authors: Simone Dertschnig Jakob Passweg Christoph Bucher Michael Medinger Alexandar Tzankov Source Type: research
